CN1872249A - Application of medication of containing red peony root in resistant medication anti aspirin - Google Patents
Application of medication of containing red peony root in resistant medication anti aspirin Download PDFInfo
- Publication number
- CN1872249A CN1872249A CN 200510013592 CN200510013592A CN1872249A CN 1872249 A CN1872249 A CN 1872249A CN 200510013592 CN200510013592 CN 200510013592 CN 200510013592 A CN200510013592 A CN 200510013592A CN 1872249 A CN1872249 A CN 1872249A
- Authority
- CN
- China
- Prior art keywords
- aspirin
- application
- radix
- medicine
- medication
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An application of the medicinal composition consisting of 5 Chinese-medicinal materials including red sage root, notoginseng, red peony root, alismatis rhizome, liquorice, etc, etc in preparing the medicines for treating the aspirin-resistant cardiovascular disease is disclosed.
Description
Technical field
The present invention relates to field of medicaments, specifically, the present invention relates to the application of a kind of Chinese medicine composition in preparation treatment resistant medication of aspirin.
Background technology
Aspirin (Aspirin) claim aspirin or aspirin again, is applied to clinical existing more than 80 year history, is a kind of ancient analgesic, analgesic.Along with the going deep into of prostaglandin research, aspirin there has been new understanding again in recent years: analgesic except being used for traditionally clinically, analgesia, the antiinflammatory, also be used for antiplatelet aggregation etc.Clinical trial shows that aspirin is the effective antiplatelet drug of cardiovascular and cerebrovascular disease high-risk patient primary prevention, and is also effective to the secondary prevention of myocardial infarction and ischemic vascular events.
But use the aspirin of therapeutic dose at present clinically, still there is part cardiovascular and cerebrovascular disease patient that coronary artery thrombus and apoplexy have taken place, strengthen therapeutic dose, not only fail to reach treatment and prevention purpose, and untoward reaction increases, this phenomenon be called " aspirin resistance " (Aspirin Resistance, AR).
Through long term follow-up, reason is as follows: first platelet is by other pathway activations, can not be blocked [Valles J by aspirin, Santos MT, Aznar J, et al.Erythrocyte Promotion of platelet reactivity decreases the effectivenessof aspirin as an antithrombotic therapeutic modality:the effect of low-dose aspirin is less thanoptimal in patients with vascular disease due to prothrombotic effects of erythrocytes on plateletreactivity.Circulation, 1998; 97:350-355]; The dosage that second some needs of patients is bigger than routine dose just can obtain best thromboembolism preventing effect, there is not evidence to show relevant [the Patrono C.Prevention ofmyocardial infarction and stroke by aspirin:different mechanisms of aspirin thromboembolism preventing effect with dosage? Different dosage? Thromb.Res., 1998; 92:S7-S12]; Although using the routine dose aspirin, the 3rd some patient also can generate TXA
2[Tayllor DW, Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:arandomized controlled trail; ASA and Carotid Endarterectomy (ACE) Trial Collaborators.Lancet, 1999; 353:2179-2184].
Studies show that the generation of AR is relevant with following mechanism.
Erythrocyte improves platelet response
Platelet-erythrocyte interacts influence platelet response, synthesizes and platelet is raised and caused aspirin resistance by platelet release reaction, eicosanoids.Erythrocyte causes TXA
2Synthetic increasing, 5-HT, β-TG and ADP discharge, generation [the Valles J that shows erythrocyte adjusting platelet eicosanoids, et al.Erythrocyte metabolically enhancescollagen-induced platelet responsiveness via increased thromboxane production, adenosinediphosphate release, and recruitment.Blood, 1991; 78:154-162].
Arachidonic acid (PGF
2) metabolism
Arachidonic acid produces a series of bioactive PGF that have through lipid peroxidation
2See complex.F
2-isoprostanes is the important new predictor of angiopathy.Unstable angina, stable angina pectoris, ariant angina patient and healthy people take aspirin 100mg/d and measure 8-iso-PGF
2(mark of matter fat peroxidation) and 11 dehydrogenations-TXA
2(TXA
2Studies show that biosynthetic mark), unstable angina patient 8-iso-PGF
2Urinary excretion is apparently higher than stablizing patient with angina pectoris and matched group; TXA
2Excretion apparently higher than stable patient with angina pectoris.Unstable angina patient's oxidant stress increases, 8-iso-PGF
2Increase, platelet is to the increased response of other agonist.
Smoking stimulates
Smoking is the cardiovascular disease principal risk factor.Data shows that aspirin can the anticoagulant rate reduce platelet aggregation [the Davis JW that causes, et al Cigarette smoking-induced enhancement of platelet function:lack ifprevention by aspirin in men with coronary artery disease.J Lab Clin Med, 1982; 126:637-639].Platelet aggregation rate reduces after the smoking.Take aspirin before non-smoker and the smoking addiction person smoking and can prevent that platelet aggregation rate from descending.
The catecholamine levels platelet increasing is assembled to be increased
External platelet shows adrenergic sensitivity and has contact [Larsson PT et al between platelet activation that catecholamine causes and the acute coronary syndrome, Norepinephrine-induced human platelet activation in vivo is only partlycounteracted by aspirin.Circulation, 1994; 89:1951-1957].40 patients of acute myocardial infarction are divided into warfarin group and aspirin group at random.Get blood before and after the bicycle ergometor exercise, relatively two groups baseline characteristic, movement time and maximum heart rate.The warfarin group obviously reduces than aspirin group platelet aggregation rate when baseline, illustrates that aspirin has the effect of antiplatelet aggregation.Two groups platelet aggregation rate all reduces during motion, shows that the platelet aggregation ability increases.Its reason may be that the noradrenaline levels increase causes platelet activation.
Platelet increases the sensitivity of collagen
Collagen is the agonist of physiological important platelet aggregation.Two experimental study aspirin reply and collagen between relation.Before aspirin 324mg/kg is taken in a test (n=8 healthy male), measure the bleeding time after taking medicine 2 hours, distinguish aspirin respondent and nonresponder.87 of philtrums have participated in second test, give collagen 0.15-4 μ g/ml and determine aspirin respondent and the nonresponder's platelet sensitivity to collagen.Among 8 patients of first test, 5 aspirin respondents, 3 nonresponders.Aspirin respondent and the nonresponder preceding bleeding time indifference [(408 ± 121) and (330 ± 30) second, P＞0.05] of taking medicine has significant difference [(720 ± 225) and (330 ± 52) second] after taking medicine.Among 7 patients of second test, 4 aspirin respondents, 3 nonresponders.Aspirin respondent and the nonresponder preceding bleeding time indifference [(405 ± 52) and (357 ± 31) second of taking medicine, P＞0.05], significant difference [(623 ± 189) and (345 ± 54) second] [Kawasaki T is arranged after taking medicine, el at.Incresed platelet sensitivity to cllagen in individuals resistant to low aspirin.Stroke, 2000; 31:591-595].
Cycloxygenase-2 (COX-2) (p900)
Cox is the synthetic rate-limiting enzyme of prostaglandin.Cox-1 expresses in most cells and tissue.In the great majority tissue, can not detect under the mRNA of Cox-2 and the protein normal condition.[Weber AA, et al.Cyclooxygenase-2 in human platelet as a possible factor in aspirin resistance.Lancet, 1993 such as nearest Webr; 353:900] report that protein and the mRNA of Cox-2 express in healthy people's circulation platelet, this may be a reason of aspirin resistance.
Drug interaction
The interaction of aspirin and other nonsteroidal anti inflammatory medicines (NSAIDS) can weaken aspirin to hematoblastic effect.Aspirin needs at first to combine lysine-the 120th, the coefficient site of all NSAIDS with lysine-120 to the acetylation of serine residue.NSAIDS is stronger to the affinity of lysine-120, thereby has stoped the inhibitory action of aspirin to platelet Cox-1.
More than set forth possible mechanisms of aspirin resistance.Clear and definite platelet activation mechanism and reversible risk factor help to reduce the generation of aspirin resistance, improve patient's prognosis.
The said aspirin resistance of the present invention can not effectively stop thromboxane A after being meant and taking aspirin
2Synthetic, promptly aspirin has lost the protective effect to cardio-cerebrovascular, this phenomenon is referred to as aspirin resistance.Concerning Most patients, aspirin can make cardiovascular danger reduce by 25%, but the patient of aspirin resistance uses the aspirin for treatment cardiovascular disease, can not prevent the generation of cardiovascular event, can increase the incidence rate of heart infarction and apoplexy on the contrary, these find the use of restriction aspirin.Therefore, these cardiovascular disease are referred to as aspirin repellency cardiovascular disease in the middle of the present invention, particularly refer to coronary heart disease, the angina pectoris of using aspirin for treatment invalid.The present invention will be referred to as the medicine of anti-aspirin resistance to the medicine that aspirin repellency cardiovascular disease has a therapeutical effect, and this therapeutical effect is referred to as anti-aspirin resistance effect.
At present, the report for the treatment aspirin resistance also is not a lot.[Effeets of pretreatment withelopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneouscoronary intervention:the PCI-CURE study.Lancet, 2001] such as Yusuf S have been reported to add on the basis of aspirin for treatment and have been adjoined Gray with chlorine and can reduce the incidence rate that Acute Coronary Syndrome Patients comprises the early stage and secular serious cardiovascular incident of patient of percutaneous coronary intervention (pci).
The Chinese medicine blood-regulating drug, particularly the blood-activating stasis-removing kind medicine is the medicine that ancient Chinese medicine doctor is used always, this class medicine has the effect of promoting blood flow to regulate menstruation, removing blood stasis Xiao Disorder, blood-activating analgetic, detumescence and promoting granulation, modern pharmacology confirms, blood-regulating drug has the expansion coronary artery, increases coronary flow, reduce myocardial oxygen consumption, reduce peripheral vascular resistance, anticoagulant, microcirculation improvement, suppress thrombosis, fortifying fibre protein dissolution activity, anticoagulation system, microcirculation improvement, effects such as smooth muscle spasm are alleviated in blood pressure lowering.Find that through secular clinical research the traditional Chinese medical science thinks that the etiology and pathology of coronary heart disease is many because " imbalance of YIN and YANG, mechanism of qi be contrary to cause disorderly that the painstaking effort stasis of blood stagnates, blockage of the cardiac vessels, stagnation of QI and blood may bring about pain ".According to mentioned above principle, the someone has chosen Radix Notoginseng, Radix Paeoniae Rubra, Fructus Citri Sarcodactylis, Rhizoma Alismatis, Radix Glycyrrhizae and has made preparation, and said preparation has blood circulation promoting and blood stasis dispelling, and regulating QI to relieve pain has the expansion coronary vasodilator, and the effect of blood flow increasing is used for the uncomfortable in chest and angina pectoris of coronary heart disease.Research to said preparation at present mainly concentrates in the research of angina pectoris, and the effect of relevant said preparation treatment aspirin resistance does not appear in the newspapers as yet.In order to alleviate the phenomenon that can produce aspirin resistance when cardio-cerebral vascular disease patient uses aspirin Drug therapy cardiovascular and cerebrovascular disease, some researchers are being sought the medicine that can substitute or alleviate the aspirin resistance phenomenon at present, the present invention tests at present more present medicines just on this basis, in the hope of finding its new medicine use, easily produce the aspirin resistance phenomenon to solve present aspirin medication.
Summary of the invention
The object of the present invention is to provide the application of a kind of Chinese medicine composition in the medicine of the anti-aspirin resistance of preparation.
Described Chinese medicine composition is by comprising that following crude drug makes: Radix Notoginseng 15～60g, Radix Paeoniae Rubra 250～1000g, Fructus Citri Sarcodactylis 150～600g, Rhizoma Alismatis 150～600g, Radix Glycyrrhizae 25～100g; Preferred described Chinese medicine composition is by comprising that following crude drug makes: Radix Notoginseng 20～40g, Radix Paeoniae Rubra 400～600g, Fructus Citri Sarcodactylis 200～400g, Rhizoma Alismatis 200～400g, Radix Glycyrrhizae 35～60g; Best described Chinese medicine composition is by comprising that following crude drug makes: Radix Notoginseng 30g, Radix Paeoniae Rubra 500g, Fructus Citri Sarcodactylis 300g, Rhizoma Alismatis 300g, Radix Glycyrrhizae 50g.
The preparation of the effective ingredient of described Chinese medicine composition can be adopted following method: water extraction, decoction and alcohol sedimentation technique, extraction, infusion process, percolation, reflux extraction, continuous backflow extraction method, macroreticular resin absorbing method preparation.For example, these crude drug pulverize mix homogeneously can be made powder takes after mixing it with water; Also can be with these medicines decocting together, the condensed water decocting liquid is made oral liquid then; But, preferably adopt following technology to extract, but this can not limit protection scope of the present invention to raw material in order to make each crude drug of this medicine bring into play drug effect better.
The preparation method of described Chinese medicine composition can adopt following steps:
Get Radix Notoginseng 30g, Radix Paeoniae Rubra 500g, Fructus Citri Sarcodactylis 300g, Rhizoma Alismatis 300g, Radix Glycyrrhizae 50g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 1 hour, collecting decoction filtered, filtrate is concentrated into relative density 1.06 (65～75 ℃), room temperature to be chilled to, and 90% ethanol that adds 1 times of amount stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.30 (65～75 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 90% ethanol, reflux secondary, each 2 hours, after reclaiming ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 5% stirs evenly drying, make granule, be pressed into 500, sugar coating, promptly.
Described Chinese medicine composition can be made any preparation on the pharmaceutics; Preferably make tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ointment, plaster, spray, drop pill dosage form.
More than form when producing and to increase or to reduce according to corresponding ratio, as large-scale production can be unit with kilogram or with the ton, small-scale production can be unit with the gram also, and weight can increase or reduce, but the crude drug material weight proportion constant rate between each composition.
In order to understand essence of the present invention better,, its new purposes in pharmaceutical field is described below by the result of the test of this pharmaceutical composition of clinical observation at anti-" aspirin resistance ".
The present invention adopts the research method to aspirin resistance commonly used at present, by measuring platelet aggregation rate, judge whether the patient has the effect that reduces aspirin resistance after taking medicine of the present invention, the present invention passes through clinical research observation, proved the application of medicine of the present invention in the medicine of the anti-aspirin resistance of preparation, medicine of the present invention has the effect of anti-aspirin resistance, in order to understand the present invention better, the clinical test results with medicine of the present invention illustrates its new purposes in pharmaceutical field below.
Experimental example medicine of the present invention (according to the preparation of embodiment 1 preparation method) reduces aspirin resistance effect experiment
We carry out aspirin to 20 Yu Jia cadre's sanitarium retired cadres and family members under the Beijing Military Area Command and detect examination, filter out 86 of aspirin resistance patients (56 of men altogether, 30 of woman, 70.9 ± 10.9 years old age), find that the aspirin resistance incidence rate is about 15.6%.The aspirin resistance patient is divided into (55 of combination group; Unite and use aspirin and medicine of the present invention), single with medicine group of the present invention (31, the aspirin of stopping using is singly used medicine of the present invention), measure the platelet maximum agglutination rate once more after treating for 2 weeks.
Method:
One. inclusion criteria
1. take low-dosage aspirin continuously and surpass 2 all persons
2. use U.S. CHRON-LOG AGGREGOMETER 540VS and detect the platelet maximum agglutination rate of its arachidonic acid-induction greater than 30%
Meeting above-mentioned two persons simultaneously can be selected in
Two. exclusion standard:
1. disease in the blood system hemorrhage especially;
2. cancer
3. chronic obstructive pulmonary disease
The person promptly is excluded to meet the one
Three. grouping:
Combination group: select 55 aspirin resistance patients at random, continue to use aspirin, add simultaneously with 12 slices/day of 2 all medicines of the present invention.
Single with medicine group of the present invention: select 31 aspirin resistance patients at random, inactive aspirin is used medicine of the present invention instead, and is oral, one time 4,3 times on the one, 2 weeks.
Four. curative effect determinate standard
Produce effects: the platelet maximum agglutination rate is less than 30% (effect is equal to normal aspirin effect)
Effectively: the platelet maximum agglutination rate is greater than 30%, but is lower than for 80% (the platelet activation value normally suppresses effect but be lower than aspirin in normal range)
Invalid: the maximum agglutination rate excursion is ± 10% before and after the treatment
Raise: maximum agglutination rate changes greater than 10% before and after the treatment
Effective percentage=(produce effects number+effective number)/total number of persons
The result
One, the medication combined use of aspirin resistance aspirin and the present invention
1. treatment effective percentage
| Therapeutic effect | Number | Ratio % |
| The produce effects enabledisable raises | 45 1 4 5 | 82 2 7 9 |
The total effective rate of aspirin and the medication combined use of the present invention reaches 84% (46/55)
2. compare before and after the platelet maximum agglutination rate:
Before the treatment (67.8 ± 25.6), treatment 2 week backs (27.8 ± 22.4) are through paired t-test: p＜0.01; Platelet aggregation rate
Embodiment 2:
Get Radix Notoginseng 15g, Radix Paeoniae Rubra 250g, Fructus Citri Sarcodactylis 150g, Rhizoma Alismatis 600g, Radix Glycyrrhizae 25g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 1 hour, collecting decoction filtered, filtrate is concentrated into relative density 1.02～1.10 (65～75 ℃), room temperature to be chilled to, and 80% ethanol that adds 2 times of amounts stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.30 (65～75 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 80% ethanol, the reflux secondary, and each 2 hours, behind the recovery ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 5% stirs evenly, and drying is made granule, makes electuary, promptly.
Embodiment 3:
Get Radix Notoginseng 60g, Radix Paeoniae Rubra 1000g, Fructus Citri Sarcodactylis 150g, Rhizoma Alismatis 150g, Radix Glycyrrhizae 100g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 2 hours, collecting decoction filtered, filtrate is concentrated into relative density 1.16 (65～70 ℃), room temperature to be chilled to, and 70% ethanol that adds 3 times of amounts stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.20～1.25 (65～75 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 70% ethanol, reflux secondary, each 2 hours, after reclaiming ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 8% stirs evenly drying, make granule, encapsulated, make 1000, promptly.
Embodiment 4:
Get Radix Notoginseng 20g, Radix Paeoniae Rubra 400g, Fructus Citri Sarcodactylis 200g, Rhizoma Alismatis 200g, Radix Glycyrrhizae 35g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 2 hours, collecting decoction filtered, filtrate is concentrated into relative density 1.02～1.10 (65 ℃), room temperature to be chilled to, and 75% ethanol that adds 5 times of amounts stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.05～1.25 (65 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 75% ethanol, reflux secondary, each 3 hours, after reclaiming ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 5% stirs evenly drying, make granule, be pressed into 500, sugar coating, promptly.
Embodiment 5:
Get Radix Notoginseng 40g, Radix Paeoniae Rubra 600g, Fructus Citri Sarcodactylis 400g, Rhizoma Alismatis 400g, Radix Glycyrrhizae 60g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 2.5 hours, collecting decoction filtered, filtrate is concentrated into relative density 1.02～1.25 (75 ℃), room temperature to be chilled to, and 85% ethanol that adds 2.5 times of amounts stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.30 (65～75 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 85% ethanol, reflux secondary, each 2.5 hours, after reclaiming ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 10% stirs evenly drying, make granule, be pressed into 1000, sugar coating, promptly.
The average range of decrease is 49.12%.
Annotate: value before reduction amplitude=(being worth after value-medication before the medication)/medication
Two. aspirin resistance stops aspirin, list medicine of the present invention
1. treatment effective percentage
| Therapeutic effect | Number | Ratio % |
| The produce effects enabledisable raises | 12 4 7 8 | 38 13 23 26 |
Stop aspirin, list medicine of the present invention, the total effective rate that aspirin resistance is treated reaches 51% (16/31)
2. compare before and after the platelet maximum agglutination rate:
Before the treatment (82.8 ± 15.5), treatment 2 week backs (66.8 ± 30.1) are through paired t-test: p＜0.05; The average range of decrease of platelet aggregation rate is 17.51%.
Annotate: value before reduction amplitude=(being worth after value-medication before the medication)/medication
Conclusion: to the aspirin resistance person, use aspirin and Drug therapy of the present invention can obviously lower platelet aggregation rate simultaneously, effective percentage is 84%, and the average range of decrease is 49.12%; Single its effective percentage is 51% with Drug therapy aspirin resistance of the present invention, and the average range of decrease is 17.51%.Presentation of results is to the invalid cardiovascular patient of independent use aspirin for treatment, medicine of the present invention and aspirin share has the effect of good curing aspirin resistance, use Drug therapy aspirin resistance of the present invention that effect is preferably also arranged separately, but the effect not as good as with the aspirin combination group, whether medicine of the present invention reduces aspirin resistance by other mechanism of action, the further research of still needing.
Medicine of the present invention is to be prepared from by following examples, and following specific embodiment is an explanation of the invention, can not limit the present invention.
The specific embodiment
Embodiment 1:
Get Radix Notoginseng 30g, Radix Paeoniae Rubra 500g, Fructus Citri Sarcodactylis 300g, Rhizoma Alismatis 300g, Radix Glycyrrhizae 50g is standby;
The above five tastes, Radix Notoginseng, Radix Glycyrrhizae pulverize separately become fine powder; Radix Paeoniae Rubra, Rhizoma Alismatis decoct with water secondary, and each 1 hour, collecting decoction filtered, filtrate is concentrated into relative density 1.06 (65～75 ℃), room temperature to be chilled to, and 90% ethanol that adds 1 times of amount stirs evenly, leave standstill, get supernatant and filter, filtrate is concentrated into the clear paste of relative density 1.30 (65～75 ℃); Other gets Fructus Citri Sarcodactylis and is ground into coarse powder, and it is an amount of to add 90% ethanol, reflux secondary, each 2 hours, after reclaiming ethanol, stir evenly with above-mentioned clear paste, the starch that adds Radix Notoginseng, Radix Glycyrrhizae fine powder and clear paste weight 5% stirs evenly drying, make granule, be pressed into 500, sugar coating, promptly.
Claims (7)
1, the application of a kind of pharmaceutical composition in the low anti-medicine of the anti-aspirin of preparation, wherein this drug composition is by comprising that following crude drug makes: Radix Notoginseng 15～60g, Radix Paeoniae Rubra 250～1000g, Fructus Citri Sarcodactylis 150～600g, Rhizoma Alismatis 150～600g, Radix Glycyrrhizae 25～100g.
2, application as claimed in claim 1, wherein this drug composition is by comprising that following crude drug makes: Radix Notoginseng 20～40g, Radix Paeoniae Rubra 400～600g, Fructus Citri Sarcodactylis 200～400g, Rhizoma Alismatis 200～400g, Radix Glycyrrhizae 35～60g.
3, application as claimed in claim 1, wherein this drug composition is by comprising that following crude drug makes: Radix Notoginseng 30g, Radix Paeoniae Rubra 500g, Fructus Citri Sarcodactylis 300g, Rhizoma Alismatis 300g, Radix Glycyrrhizae 50g.
4,, it is characterized in that described compositions is tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, sucks agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, solution, ointment, plaster, spray, drop pill as any one described application in the claim 1～3.
5,, it is characterized in that the application of this pharmaceutical composition in the medicine of preparation treatment aspirin repellency cardiovascular and cerebrovascular disease as any one described application in the claim 1～3.
6, application as claimed in claim 5 is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant the invalid cardiovascular and cerebrovascular disease of use aspirin for treatment.
7, application as claimed in claim 6 is characterized in that said aspirin repellency cardiovascular and cerebrovascular disease is meant invalid coronary heart disease, the angina pectoris of use aspirin for treatment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510013592 CN1872249A (en) | 2005-06-01 | 2005-06-01 | Application of medication of containing red peony root in resistant medication anti aspirin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510013592 CN1872249A (en) | 2005-06-01 | 2005-06-01 | Application of medication of containing red peony root in resistant medication anti aspirin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1872249A true CN1872249A (en) | 2006-12-06 |
Family
ID=37482958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510013592 Pending CN1872249A (en) | 2005-06-01 | 2005-06-01 | Application of medication of containing red peony root in resistant medication anti aspirin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1872249A (en) |
-
2005
- 2005-06-01 CN CN 200510013592 patent/CN1872249A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1745768B (en) | Use of medicine containing Milkvetch Root against aspirin | |
| CN1714859A (en) | Use of composition containing red-rooted salvia root in preparing medicine for treating anti-aspirin | |
| CN1714836A (en) | Application of a kind of medicine in preparation of medicine for treating aspirin resistance | |
| CN1714837A (en) | Use of medicine containing haw in preparing medicine for treating anti-aspirin | |
| CN1872317A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1872315A (en) | Application of medication of containing spatholobus stem in resistant medication anti aspirin | |
| CN1872249A (en) | Application of medication of containing red peony root in resistant medication anti aspirin | |
| CN1724026A (en) | Application of medicinal composition for preparing medicine for treating aspirin-resistance | |
| CN1872312A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1723974A (en) | Application of medicine contg. ligusticum wallichii for preparing medicine of anti-aspirn-resistance | |
| CN1724046A (en) | Application of medicine contg. sealwort for preparing medicine of anti-aspirin-resistance | |
| CN1724035A (en) | Application of medicine contg. wilsonii used for anti aspirin resistance | |
| CN1872316A (en) | Medication of containing astragalus root in application for treating resistant medication of aspirin | |
| CN1745764A (en) | Use of depot containing safflower against aspirin | |
| CN1872176A (en) | Application of medication of containing red sage root in treating resistant medication of aspirin | |
| CN1785271A (en) | Applicalsion of medicine containing salvia in anriaspirin medicine | |
| CN1714822A (en) | Use of medicine containing ligusticum vallichii in preparing medicine for treating anti-aspirin | |
| CN1872313A (en) | Medication of containing curcuma root in application for treating resistant medication of aspirin | |
| CN1745804A (en) | Use of medicine containing Danshen Root inpreparing medicine against aspirin | |
| CN1745767A (en) | Use of depot containing Chuanxiong against aspirin | |
| CN1723983A (en) | Application of medicinal composition contg. Astragalus mongholicus in preparing medicine for treating aspirin-resistance disease | |
| CN1872314A (en) | Application of medication of containing spatholobus stem in resistant medication anti aspirin | |
| CN1714831A (en) | Use of medicinal composition in preparing medicine for treating anti aspirin | |
| CN1872177A (en) | Application of medication of containing red sage root in resistant medication anti aspirin | |
| CN1714825A (en) | Use of composition in preparing medicine for treating anti-aspirin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |